SMAD4 and cancer: Analysis of 55,308 cancers registered in a public database revealed a significant trend toward co-occurrence of mutations in KRAS and SMAD4 (p < 0.0001; see Section 4.4 for details), indicating a potential synergistic role of these mutations in cancer survival and progression (Figure 4A) [11].